MIR-219-5p plays a tumor suppressive role in colon cancer by targeting oncogene Sall4

Oncology Reports

Volumn 34, Issue 4, 2015, Pages 1923-1932

  Cheng, Ji ^a   Deng, Rui ^a   Zhang, Peng ^a   Wu, Chuanqing ^a   Wu, Ke ^a   Shi, Liang ^a   Liu, Xinghua ^a   Bai, Jie ^a   Deng, Meizhou ^a   Shuai, Xiaoming ^a   Gao, Jinbo ^a   Wang, Guobin ^a   Tao, Kaixiong ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Colon cancer; MIR 219 5p; MiRNA; Sall4

Indexed keywords

MICRORNA; MICRORNA 219 5P; UNCLASSIFIED DRUG; MIRN219 MICRORNA, HUMAN; SALL4 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

APOPTOSIS; ARTICLE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL ARTICLE; COLON CANCER; COLON CARCINOGENESIS; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; ONCOGENE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SALL4 GENE; WESTERN BLOTTING; BIOSYNTHESIS; CELL MOTION; COLONIC NEOPLASMS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; TUMOR CELL LINE; TUMOR INVASION; TUMOR SUPPRESSOR GENE;

APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COLONIC NEOPLASMS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; MICRORNAS; NEOPLASM INVASIVENESS; TRANSCRIPTION FACTORS;

EID: 84939170145     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.4168     Document Type: Article

References (34)

1. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin 65: 5-29, 2015.
2. Li L and Ma BB: Colorectal cancer in Chinese patients: Current and emerging treatment options. Onco Targets Ther 7: 1817-1828, 2014.
3. Tokarz P and Blasiak J: The role of microRNA in metastatic colorectal cancer and its significance in cancer prognosis and treatment. Acta Biochim Pol 59: 467-474, 2012.
4. Nana-Sinkam SP and Croce CM: Clinical applications for microRNAs in cancer. Clin Pharmacol Ther 93: 98-104, 2013.
5. Cui Y, Bai Y, Wang XD, Liu B, Zhao Z and Wang LS: Differential expression of miRNA in rat myocardial tissues under psychological and physical stress. Exp Ther Med 7: 901-906, 2014.
6. Shim SM, Jung SY, Nam HY, Kim HR, Lee MH, Kim JW, Han BG and Jeon JP: Network signatures of cellular immortalization in human lymphoblastoid cell lines. Biochem Biophys Res Commun 441: 438-446, 2013.
7. H uang N, Lin J, Ruan J, Su N, Qing R, Liu F, He B, Lv C, Zheng D and Luo R: MiR-219-5p inhibits hepatocellular carcinoma cell proliferation by targeting glypican-3. FEBS Lett 586: 884-891, 2012.
8. Huang C, Cai Z, Huang M, Mao C, Zhang Q, Lin Y, Zhang X, Tang B, Chen Y, Wang X, et al: MIR-219-5p modulates cell growth of papillary thyroid carcinoma by targeting estrogen receptor. J Clin Endocrinol Metab 100: E204-E213, 2015.
9. Rao SA, Arimappamagan A, Pandey P, Santosh V, Hegde AS, Chandramouli BA and Somasundaram K: MIR-219-5p inhibits receptor tyrosine kinase pathway by targeting EGFR in glioblastoma. PLoS One 8: e63164, 2013.
10. Forghanifard MM, Moghbeli M, Raeisossadati R, Tavassoli A, Mallak AJ, Boroumand-Noughabi S and Abbaszadegan MR: Role of SALL4 in the progression and metastasis of colorectal cancer. J Biomed Sci 20: 6, 2013.
11. Ardalan Khales S, Abbaszadegan MR, Abdollahi A, Raeisossadati R, Tousi MF and Forghanifard MM: SALL4 as a new biomarker for early colorectal cancers. J Cancer Res Clin Oncol 141: 229-235, 2015.
12. Böhm J, Sustmann C, Wilhelm C and Kohlhase J: SALL4 is directly activated by TCF/LEF in the canonical Wnt signaling pathway. Biochem Biophys Res Commun 348: 898-907, 2006.
13. He J, Zhang W, Zhou Q, Zhao T, Song Y, Chai L and Li Y: Low-expression of microRNA-107 inhibits cell apoptosis in glioma by upregulation of SALL4. Int J Biochem Cell Biol 45: 1962-1973, 2013.
14. Prenen H, Vecchione L and Van Cutsem E: Role of targeted agents in metastatic colorectal cancer. Target Oncol 8: 83-96, 2013.
15. Oestreicher P: Sequencing therapies: The role of targeted agents in metastatic colorectal cancer. ONS Connect 22 (Suppl 8): 37-38, 2007.
16. Iqbal N and Iqbal N: Imatinib: A breakthrough of targeted therapy in cancer. Chemother Res Pract 2014: 357027, 2014.
17. Balduzzi S, Mantarro S, Guarneri V, Tagliabue L, Pistotti V, Moja L and D'Amico R: Trastuzumab-containing regimens for metastatic breast cancer. Cochrane Database Syst Rev 6: CD006242, 2014.
18. G ustavsson B, Carlsson G, Machover D, Petrelli N, Roth A, Schmoll HJ, Tveit KM and Gibson F: A review of the evolution of systemic chemotherapy in the management of colorectal cancer. Clin Colorectal Cancer 14: 1-10, 2015.
19. Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M, Thibodeau SN, Smyrk TC, Sinicrope FA, Chan E, Gill S, et al: Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: A randomized trial. JAMA 307: 1383-1393, 2012.
20. Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, Sigurdsson F, Kure E, Ikdahl T, Skovlund E, et al: Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: The NORDIC-VII study. J Clin Oncol 30: 1755-1762, 2012.
21. Seymour MT: Adjuvant bevacizumab in colon cancer: Where did we go wrong? Lancet Oncol 13: 1176-1177, 2012.
22. Sculier JP, Berghmans T and Meert AP: Advances in target therapy in lung cancer. Eur Respir Rev 24: 23-29, 2015.
23. Zhang Y, Wang X, Wang Z, Tang H, Fan H and Guo Q: MIR-182 promotes cell growth and invasion by targeting forkhead box F2 transcription factor in colorectal cancer. Oncol Rep 33: 2592-2598, 2015.
24. Tang L, Chen F, Pang EJ, Zhang ZQ, Jin BW and Dong WF: MicroRNA-182 inhibits proliferation through targeting oncogenic ANUBL1 in gastric cancer. Oncol Rep 33: 1707-1716, 2015.
25. Jiang Z, Cushing L, Ai X and Lü J: MIR-326 is downstream of Sonic hedgehog signaling and regulates the expression of Gli2 and smoothened. Am J Respir Cell Mol Biol 51: 273-283, 2014.
26. Leung WK, He M, Chan AW, Law PT and Wong N: Wnt/Catenin activates MiR-183/96/182 expression in hepatocellular carcinoma that promotes cell invasion. Cancer Lett 362: 97-105, 2015.
27. Yong KJ, Gao C, Lim JS, Yan B, Yang H, Dimitrov T, Kawasaki A, Ong CW, Wong KF, Lee S, et al: Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. N Engl J Med 368: 2266-2276, 2013.
28. Gao C, Kong NR and Chai L: The role of stem cell factor SALL4 in leukemogenesis. Crit Rev Oncog 16: 117-127, 2011.
29. Yang J, Chai L, Liu F, Fink LM, Lin P, Silberstein LE, Amin HM, Ward DC and Ma Y: Bmi-1 is a target gene for SALL4 in hematopoietic and leukemic cells. Proc Natl Acad Sci USA 104: 10494-10499, 2007.
30. Gao C, Dimitrov T, Yong KJ, Tatetsu H, Jeong HW, Luo HR, Bradner JE, Tenen DG and Chai L: Targeting transcription factor SALL4 in acute myeloid leukemia by interrupting its interaction with an epigenetic complex. Blood 121: 1413-1421, 2013.
31. Kang W, Tong JH, Lung RW, Dong Y, Zhao J, Liang Q, Zhang L, Pan Y, Yang W, Pang JC, et al: Targeting of YAP1 by microRNA-15a and microRNA-16-1 exerts tumor suppressor function in gastric adenocarcinoma. Mol Cancer 14: 52, 2015.
32. Z hang ZW, Men T, Feng RC, Li YC, Zhou D and Teng CB: MIR-375 inhibits proliferation of mouse pancreatic progenitor cells by targeting YAP1. Cell Physiol Biochem 32: 1808-1817, 2013.
33. Yu SJ, Hu JY, Kuang XY, Luo JM, Hou YF, Di GH, Wu J, Shen ZZ, Song HY and Shao ZM: MicroRNA-200a promotes anoikis resistance and metastasis by targeting YAP1 in human breast cancer. Clin Cancer Res 19: 1389-1399, 2013.
34. Gebert LF, Rebhan MA, Crivelli SE, Denzler R, Stoffel M and Hall J: Miravirsen (SPC3649) can inhibit the biogenesis of MIR-122. Nucleic Acids Res 42: 609-621, 2014.